Biotech Startups

Hospital-based therapies for acute, life-threatening neurological conditions. (NASDAQ: EDGE)

1 investor

Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a first-in-class treatment candidate for hematologic malignancies and genetically-defined solid tumors. The company focuses on addressing unmet medical needs in cancer treatment.

1 investor

Edison Agro Sciences develops bio-based synthetic rubber from sunflower crops as an alternative to petrochemical and natural rubber for industrial applications. The company processes agricultural waste from sunflower farming to create environmentally responsible rubber products for manufacturers seeking to reduce carbon emissions and comply with regulatory requirements.

1 investor

EditCo manufactures arrayed CRISPR guide RNA libraries for functional genomics screening, using its proprietary XDel technology to achieve high-efficiency gene knockouts in human and mouse cell lines. The company serves research institutions and biotech companies conducting target discovery and validation studies.

1 investor

A Berkeley spinout developing a new generation of medicines for the brain and other hard-to-treat tissues using breakthrough science from UC Berkeley and the Innovative Genomics Institute.

1 investor

Edwards Lifesciences develops innovative medical technologies for treating cardiovascular disease, focusing on structural heart interventions. The company serves patients and healthcare providers globally through partnerships with clinicians and healthcare stakeholders.

1 investor

EDX Medical is a healthcare/medical services company led by experienced directors from the pharmaceutical, biotech, and medical sectors. The company appears to operate in the medical diagnostics and laboratory services space based on its team's expertise in laboratory management, pathology, and life sciences.

1 investor

Effa, based in the United States, makes disposable personal care products intended as alternatives to conventional plastic items. Its toothbrush uses a handle made from recycled paper with a corn starch–based laminate coating and bristles from a nylon formulated to break down more quickly, and is sold to consumers looking for lower-waste options.

1 investor

Efor provides quality and compliance consulting and AI-enabled digital tools for Life Sciences companies, covering project management, CQV & CSV activities, quality management, process industrialization and operational excellence. It serves pharmaceutical and health product manufacturers, helping them meet cGMP regulatory requirements across the industrial value chain.

1 investor

Egalet develops medicines for people living with moderate to severe pain, including approved and licensed pain products. It operates in the pharmaceutical industry focused on pain treatment.

1 investor

A digital health resource platform providing medical professionals with educational information and clinical resources about transthyretin amyloid cardiomyopathy (ATTR-CM) and related cardiac and neurological conditions.

1 investor

1 investor

Eikonizo develops small molecule therapeutics targeting neurodegenerative and cardiorenal diseases. The company is focused on creating novel, disease-modifying treatments to improve patient outcomes.

1 investor

Eilean Therapeutics is a small molecule oncology drug discovery company developing pan-variant therapies that target resistance mechanisms in hematologic malignancies. Founded in 2022, it focuses on creating first- and best-in-class treatments for blood cancers that have developed resistance to existing therapies.

1 investor

Eisai is a global research-based pharmaceutical company focused on neurology and oncology, with a commitment to patient-centric healthcare solutions worldwide.

1 investor

ekei labs develops precision measurement and visualization technology for epigenetic information to advance longevity and aging research. The company aims to create valuable datasets for machine learning algorithms and translate research outcomes into new health indicators for clinical use.

1 investor

EKF Diagnostics is a global diagnostics and biotechnology company that develops and manufactures point-of-care medical devices, laboratory tests, and life sciences reagents for healthcare professionals and research applications. The company operates manufacturing facilities in the US and Germany and distributes products across over 120 countries.

1 investor

Ekidna develops a lab-on-a-chip system for rapid, decentralized testing of cannabinoids, using electrochemical sensors to detect compounds in various sample types. It serves cannabis growers and product manufacturers.

1 investor

Ekso Bionics develops wearable exoskeleton robotics used to help people with paralysis stand and walk, to augment worker physical capabilities, and to support rehabilitation and R&D. It serves medical/rehabilitation and industrial markets in the healthcare robotics and medical device category.

1 investor

Eldec is a biotechnology company developing peptide-based therapeutics targeting SPLUNC1's modulation of Orai1 activity, with lead programs ELD615 and ELD607 for lung diseases such as cystic fibrosis and non-CF bronchiectasis. Its research programs are supported by NHLBI, NIAID, NIDDK, and the North Carolina Biotechnology Center.

1 investor

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS. The company's lead candidate is tegoprubart, an anti-CD40L antibody.

1 investor

ELEM develops healthcare digital twins using biosimulation technology to enable pharmaceutical and medical device companies to test and predict treatment outcomes before clinical trials. The company combines biomedical science, mechanistic modeling, AI, and high-performance computing to replicate human physiology for safer, more efficient drug and device development.

1 investor

Elemental Enzymes develops peptide and biochemical solutions to protect plants from disease and stress. The company serves agricultural markets by leveraging plant biology research to create plant protection products.

1 investor

ElementZero Biolabs produces reagents that boost the amplification of DNA and RNA targets present at very low concentrations, reporting roughly 100 times greater sensitivity than standard approaches. The chemistry is intended for point-of-care and research settings, allowing genetic markers to be detected without specialized instruments or extended protocols.

1 investor